Drug Class: Immunotherapy

Anti-Tumor Antibodies: MUC16 (CA125)

First-line treatment with/without extended (maintenance) treatment

Progression Free Survival (months)

Median length of time before the cancer comes back or gets worse

Overall Survival (months)

The length of time where half the patients in the study are still alive

No Prior Therapies

Anti-Tumor Antibodies: MUC16 (CA125)

First-line treatment with/without extended (maintenance) treatment

For more detailed information, please click on the clinical trial ID number.

Trial ID # Phase Drugs Clinical Trial Title Key Conclusion and Results
Drugs in Clinical Development
NCT01616303 II Carboplatin, Oregovomab, Paclitaxel Phase 2: A Randomized Controlled Study on Effectiveness of Chemotherapy (Carboplatin-Paclitaxel) Versus Chemo-immunotherapy (Carboplatin-Paclitaxel-Oregovomab) in Patients With Advanced Epithelial Ovarian, Adnexal or Peritoneal Carcinoma

Addition of oregovomab to carboplatin+paclitaxel and continued as maintenance treatment significantly increases PFS and OS

CarboPt+Pac+Ore vs CarboPt+Pac:

PFS: 41.8 vs 12.2 months*
OS: NR vs 43.2 months*

pub 2020

*Statistically significant result

< Return to Drug Classes

< Return to Clinical Trial Results Homepage